Literature DB >> 30976592

Atypical Case of Rosai-Dorfman Disease of the Lacrimal Gland with Adjacent Bone Erosion.

Mohammad Dahrouj1, Frederick A Jakobiec1,2, Natalie Wolkow1,2, Victoria S Starks1,3, Nahyoung Grace Lee1,3.   

Abstract

BACKGROUND/AIMS: Rosai-Dorfman disease (RDD) is a rare, self-limited disorder of unknown etiology that affects children and young adults worldwide and typically manifests as chronic, painless cervical lymphadenopathy. Orbital involvement is very rare and may be an isolated extranodal manifestation or associated with concurrent systemic disease. Adjacent bone involvement is most exceptional, and secondary optic neuropathy has never been reported.
METHODS: This is a case report with review of the literature.
RESULTS: We present a 32-year-old man who, over a 3-month period, developed worsening vision, headache, and vertical diplopia. On examination, there was decreased vision with dyschromatopsia, proptosis, and hypotropia of the left eye. CT scan of the orbits revealed a soft tissue mass inseparable from the lacrimal gland with adjacent bone erosion. Histopathologic evaluation revealed a diffuse infiltrate of histiocytes, lymphocytes, plasma cells, and neutrophils with peripolesis and emperipolesis (tunneling of lymphocytes and plasma cells in the histiocytes' cytoplasm without destruction), consistent with RDD. Resolution of symptoms as well as of the optic neuropathy was achieved with oral corticosteroids.
CONCLUSION: RDD is an important diagnosis that must be considered in the differential diagnosis of an orbital mass.

Entities:  

Keywords:  Bone lytic lesion; Lacrimal gland; Rosai-Dorfman disease; Secondary optic neuropathy

Year:  2018        PMID: 30976592      PMCID: PMC6422131          DOI: 10.1159/000489127

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  32 in total

1.  A case of Rosai-Dorfman disease involving the lacrimal gland in an elderly patient.

Authors:  Peter Beckingsale; Timothy Sullivan; Kevin Whitehead
Journal:  Orbit       Date:  2002-06

2.  Rosai-Dorfman disease and generalized AA amyloidosis: a case report.

Authors:  C Röcken; K Wieker; H J Grote; G Müller; A Franke; A Roessner
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

3.  Marginal corneal infiltrates: a possible new manifestation of sinus histiocytosis with massive lymphadenopathy.

Authors:  S Rumelt; I Cohen; U Rehany
Journal:  Cornea       Date:  2000-11       Impact factor: 2.651

4.  Lacrimal location of sinus histiocytosis (Rosai-Dorfman-Destombes disease).

Authors:  Robin Azoulay; Hervé Brisse; Paul Fréneaux; Solène Ferey; Gabriel Kalifa; Catherine Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2004-03       Impact factor: 3.825

5.  Rosai-Dorfman disease in a patient with systemic lupus erythematosus.

Authors:  Primal P Kaur; Ruth C Birbe; Raphael J DeHoratius
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

Review 6.  Atypical cellular disorders.

Authors:  Kenneth L McClain; Yasodha Natkunam; Steven H Swerdlow
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

7.  Rosai-Dorfman syndrome affecting the lacrimal gland.

Authors:  Ashwin Reddy; Bijan Beigi; Evangelos Linardos
Journal:  Orbit       Date:  2001-09

8.  Rosai-Dorfman disease presenting as bilateral lacrimal gland enlargement.

Authors:  M Lee-Wing; A Oryschak; G Attariwala; M Ashenhurst
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

Review 9.  Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review.

Authors:  Alessandro Pulsoni; Gabriel Anghel; Paolo Falcucci; Roberta Matera; Edoardo Pescarmona; Michela Ribersani; Nicoletta Villivà; Franco Mandelli
Journal:  Am J Hematol       Date:  2002-01       Impact factor: 10.047

10.  Orbital sinus histiocytosis (Rosai-Dorfman disease): a lacrimal gland involvement.

Authors:  J C Quintyn; M L Ranty; P Courville; J Métayer; A Retout
Journal:  Ophthalmologica       Date:  2002 Jul-Aug       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.